Navigation Links
Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
Date:5/28/2009

nths for those who received modified FOLFOX-6, containing oxaliplatin.
  • Of the 51 patients in the FOLPI treatment arm, 75 percent achieved disease control (defined as complete response, partial response or stable disease); two patients with a complete response, nine patients with a partial response and 27 patients with stable disease. In the FOLFOX treatment arm of 50 patients, 76 percent achieved disease control; three patients with a complete response, 11 patients with a partial response and 24 patients with stable disease.
  • Only 29 percent of the patients who received FOLPI showed evidence of neurotoxicity compared with 60 percent of patients treated with FOLFOX. In addition, 16 percent of FOLFOX-treated patients exhibited severe (Grade 3/4) neurotoxicity, whereas no FOLPI-treated patients showed evidence of severe neurotoxicity. Three different measurements of neuropathy were statistically significant for FOLPI as a potential neuropathy-sparing alternative to FOLFOX (p<0.0019).
  • With regard to hematologic toxicities, thrombocytopenia and neutropenia were more frequent and severe with the FOLPI regimen compared with FOLFOX. However, only one episode of febrile neutropenia and no bleeding complications have been observed to date. In addition, 83 percent of the planned picoplatin dose of 150 mg/meter squared was able to be delivered monthly in the 51 patients treated in the FOLPI treatment arm of the trial.
  • Nonhematologic adverse events, including gastrointestinal toxicity, were similar between the treatment groups, with the exception of alopecia, which occurred more frequently with FOLPI.

    • "We continue to be encouraged by these interim, proof-of-concept Phase 2 safety and efficacy results, which suggest the potential of picoplatin in FOLPI as a neuropathy-sparing therapeutic alternative to the use of FOLFOX for the first-line treatment of metast
    '/>"/>

    SOURCE Poniard Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
    2. Poniard Pharmaceuticals to Present New Data from Phase 2 Clinical Trials of Picoplatin in Multiple Tumor Types at the 45th Annual Meeting of the American Society of Clinical Oncology
    3. Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
    4. Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
    5. Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin
    6. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
    7. Poniard Announces Positive Efficacy and Safety Data From Phase 1 Trial of Picoplatin in Multiple Tumor Types Including Ovarian Cancer
    8. Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer
    9. Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer
    10. Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting
    11. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute

    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/25/2009)...TER,N.J.,Nov.25/PRNewswire/--TheFDAgrantedtraditio...non-nucleosidereversetranscriptaseinhibitor(NNRTI)...eintreatment-experiencedadultswhoareexperiencingvi...dotherantiretroviral(ARV)agents.Thetraditionalappr...sDUET-1andDUET-2.INTELENCEiscurrentlymarketedinthe...
    (Date:11/25/2009)...IDGE,N.J.,Nov.25/PRNewswire/--RegadoBiosciences,ap...mboticaptamerswithactivecontrolagents,announcedtha...thePiperJaffray21stAnnualHealthCareConferenceatthe...tionwillbegivenat1:10pm(EST)onTuesday,December1and...hasisontheleaddevelopmentprogram,theanticoagulants...
    (Date:11/25/2009)...Y,Calif.,Nov.25/PRNewswire-FirstCall/--Abaxis,Inc....ngpoint-of-carebloodanalysissystems,announcedtoday...,willpresentatthe21stAnnualPiperJaffrayHealthCareC...econferencewillbeheldattheNewYorkPalaceHotelinNewY...manufacturesandmarketsportablebloodanalysissystems...
    Breaking Medicine Technology:U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 2U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 3U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 4Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009 2Syngenta Acquires Innovative Bio Control Technology to Improve Usable Crop Yields 12574 1Syngenta Acquires Innovative Bio Control Technology to Improve Usable Crop Yields 12574 2Syngenta Acquires Innovative Bio Control Technology to Improve Usable Crop Yields 12574 3A WIT Technologies Releases World 26apos 3Bs First Low Cost C Stamp 28TM 29 Based Biotechnology Laboratory in a Box 12572 1A WIT Technologies Releases World 26apos 3Bs First Low Cost C Stamp 28TM 29 Based Biotechnology Laboratory in a Box 12572 2Polycom and AMD Global Telemedicine Inc To Deliver Integrated Visual And Voice Telehealth Capability To Clinicians On The Go 48554 1Polycom and AMD Global Telemedicine Inc To Deliver Integrated Visual And Voice Telehealth Capability To Clinicians On The Go 48554 2Polycom and AMD Global Telemedicine Inc To Deliver Integrated Visual And Voice Telehealth Capability To Clinicians On The Go 48554 3
    ...tes Recognized as Marker of,Treatment Success -, ...-conducted study being presented at the 59th Annua...y of Liver Diseases (AASLD) shows that,PEGASYS(R) ...in higher,sustained virological response (SVR) rat...s with another pegylated interferon.(1), Comparin...
    ...,significantly increase the risk of the most commo...ied by researchers at Massachusetts General,Hospit...November 7th issue,of American Journal of Human Ge...s Genome Project" (AGP) established three years ag...genetic risk factors, may lead to more,aggressive ...
    Other Medicine Technology:New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 2New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 3New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 4New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 5New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 6New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 7Breakthrough Mapping of Alzheimer's Genome Helps ID Four New Suspect Genes 2Breakthrough Mapping of Alzheimer's Genome Helps ID Four New Suspect Genes 3
    (Date:11/27/2009)...e; announced today that Spectrum Health (Grand Rap...se orthopedic templating solution and its TraumaCa... (PRWEB) November 27, 2009 -- Voyant Health&tr...apids, Michigan) has licensed its TraumaCad Enterp...Cad Extend workflow solution, to allow its orthope...
    (Date:11/27/2009)...turers who use medical load cells at the heart of ...ringing in technology partner Flintec early in the...medical manufacturers are calling in Flintec load ...s, ensuring that progress will not be constrained ...ed technology. , (PRWEB) ...
    (Date:11/26/2009)...andfluseasonuponus,it,smoreimportantthanevertoempl...oidillness. ,, "Weneedtobeproactivenotonlytokee...e,resick,"saidEileenFinerty,RN,MS,CIC(certifiedini...olandoccupationalhealthatHospitalforSpecialSurgery...asoneofthelowestinfectionratesofanyhospitalintheco...
    (Date:11/26/2009)...ans living with diabetes will nearly double, incre... 2034. Over the same period, spending on diabetes ...36 billion, even with no increase in the prevalenc...of Chicago report in the December issue of Diabet...vered by Medicare will rise from 8.2 million to 14...
    (Date:11/26/2009)... to strains or worse , , THURSDAY, Nov. ...with stuffing your turkey full to bursting, but yo...itcase as you pack for holiday trips. , More th...ital emergency rooms, doctors, offices, clinics an...uries, such as muscle strains, pulls and tears, ac...
    Breaking Medicine News(10 mins):Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3Health News:Pack Right for the Holidays to Avoid the ER 2
    ... Health Agency of Canada has reported that two tou..., leading to increased fears that the recent outbr...s in the country's tourist industry. The touri...dians traveling to the island to use anti-malarial...
    ...chers from Massachusetts and North Carolina have f...lised for treatment of conditions //that have resu...(COPD) such as emphysema, chronic bronchitis recei... treatment guidelines for this condition and none ...
    ...would be established in the near future for those ...nd HIV/AIDS //. Health Minister Mary Harney s...e introduction of a Bill to address insurance diff...patients especially women. These people suffe...
    ...Cancer Support of UK has taken a strong campaign a...onducted that said that in Scotland people spent//...al during treatment which is ?318 in Wales. Th...ents in Scotland and the South West can pay almost...
    ...a is a disease that spreads through mosquitoes. Ac...tion health officials there has been an increase i...bout 123 people are admitted in the hospital showi...ue. The disease is by far concentrated in North Ch...
    ...f five . Asthma-related deaths per year, in the U...ugs salmeterol or formoterol //. According to res...hese drugs should be taken off the market . Th... who inhaled the long-acting beta-agonists salmete...
    Other Medicine News:Health News:Outbreak of Malaria to Lead to Loss in Tourist Industry 2Health News:COPD Patients In US Are Not Receiving 'Ideal Care' 2Health News:Inhaler Linked To Asthma Deaths 2Health News:Inhaler Linked To Asthma Deaths 3
    Eppendorf Research Series 2100 Adjustable-volume Pipette, 20-200 l
    ...or for sub-microliter pipetting and beyond. Offers...adjustable. Features lPLUS, a direct-drive digital...le ejector buttons to fit large hands or tiny hand...ifferent lengths. Air-displacement mechanism. No r...
    ...bsystems was designed specifically to combine ergo...features such as the new fast dial system with .01...define this as a new leader in single channel pipe...a custom fit for different hand sizes. The new sho...
    ...tte is a synonym for pipetting accuracy, a smooth ...operating comfort. Its single, multifunctional but...ow-out as well as eject the tip. Product features...ccuracy and precision. Ejection sleeve can be rem...
    Medicine Products: